187 related articles for article (PubMed ID: 20022992)
1. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
[TBL] [Abstract][Full Text] [Related]
2. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
Ragnarsson O; Höybye C; Jönsson PJ; Feldt-Rasmussen U; Johannsson G; Biller BM; Koltowska-Häggström M
Eur J Endocrinol; 2012 Apr; 166(4):593-600. PubMed ID: 22258111
[TBL] [Abstract][Full Text] [Related]
3. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Bunderen CC; van Varsseveld NC; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Eur J Endocrinol; 2014 Dec; 171(6):717-26. PubMed ID: 25227133
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.
Höybye C; Ragnarsson O; Jönsson PJ; Koltowska-Häggström M; Trainer P; Feldt-Rasmussen U; Biller BM
Eur J Endocrinol; 2010 Apr; 162(4):677-84. PubMed ID: 20089548
[TBL] [Abstract][Full Text] [Related]
7. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas.
Auer MK; Stalla GK; Stieg MR
Pituitary; 2016 Oct; 19(5):461-71. PubMed ID: 27194386
[TBL] [Abstract][Full Text] [Related]
8. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
Colson A; Brooke AM; Walker D; Besser GM; Chew SL; Grossman AB; Jenkins PJ; Drake WM; Monson JP
Horm Res; 2006; 66(6):257-67. PubMed ID: 16914933
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
Johannsson G; Sunnerhagen KS; Svensson J
Clin Endocrinol (Oxf); 2004 May; 60(5):550-9. PubMed ID: 15104557
[TBL] [Abstract][Full Text] [Related]
12. Hypopituitarism in Cushing's disease.
Cavagnini F; Scacchi M; Pecori Giraldi F
J Endocrinol Invest; 2008 Sep; 31(9 Suppl):44-7. PubMed ID: 19020385
[TBL] [Abstract][Full Text] [Related]
13. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease.
Tiemensma J; Biermasz NR; Middelkoop HA; van der Mast RC; Romijn JA; Pereira AM
J Clin Endocrinol Metab; 2010 Oct; 95(10):E129-41. PubMed ID: 20660031
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of unfavorable metabolic outcome during short-term follow-up in subjects with nonfunctioning adrenal adenomas.
Yener S; Ertilav S; Secil M; Akinci B; Demir T; Kebapcilar L; Yesil S
Med Princ Pract; 2012; 21(5):429-34. PubMed ID: 22398948
[TBL] [Abstract][Full Text] [Related]
15. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
[TBL] [Abstract][Full Text] [Related]
17. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
18. Increased prevalence of anxiety-associated personality traits in patients with Cushing's disease: a cross-sectional study.
Dimopoulou C; Ising M; Pfister H; Schopohl J; Stalla GK; Sievers C
Neuroendocrinology; 2013; 97(2):139-45. PubMed ID: 22572774
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.
Attanasio AF; Mo D; Erfurth EM; Tan M; Ho KY; Kleinberg D; Zimmermann AG; Chanson P;
J Clin Endocrinol Metab; 2010 Jan; 95(1):74-81. PubMed ID: 19897679
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.
Giordano R; Picu A; Marinazzo E; D'Angelo V; Berardelli R; Karamouzis I; Forno D; Zinnà D; Maccario M; Ghigo E; Arvat E
Clin Endocrinol (Oxf); 2011 Sep; 75(3):354-60. PubMed ID: 21521323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
